156 related articles for article (PubMed ID: 38562520)
1. Neurophysiological Characteristics in Type II and Type III 5q Spinal Muscular Atrophy Patients: Impact of Nusinersen Treatment.
Li D; Sun N; Xiang L; Liu J; Wang X; Yang L; Huang S
Drug Des Devel Ther; 2024; 18():953-965. PubMed ID: 38562520
[TBL] [Abstract][Full Text] [Related]
2. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
Hoy SM
CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
[TBL] [Abstract][Full Text] [Related]
3. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen.
Richard M; Barrois R; Desguerre I; Deladrière E; Leloup-Germa V; Barnerias C; Gitiaux C
Arch Pediatr; 2024 Jan; 31(1):26-31. PubMed ID: 37989659
[TBL] [Abstract][Full Text] [Related]
4. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
[TBL] [Abstract][Full Text] [Related]
5. Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports.
Mizuno T; Kanouchi T; Tamura Y; Hirata K; Emoto R; Suzuki T; Kashimada K; Morio T
BMC Neurol; 2023 Oct; 23(1):392. PubMed ID: 37907848
[TBL] [Abstract][Full Text] [Related]
6. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
[TBL] [Abstract][Full Text] [Related]
7. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
9. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen for spinal muscular atrophy types II and III: a retrospective single-center study in South Korea.
Shin HJ; Na JH; Lee H; Lee YM
World J Pediatr; 2023 May; 19(5):450-459. PubMed ID: 36441395
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression.
Ip HNH; Yu MKL; Wong WHS; Liu A; Kwan KYH; Chan SHS
J Neuromuscul Dis; 2024; 11(2):349-359. PubMed ID: 38363614
[TBL] [Abstract][Full Text] [Related]
12. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
[TBL] [Abstract][Full Text] [Related]
13. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
14. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
[TBL] [Abstract][Full Text] [Related]
15. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
[TBL] [Abstract][Full Text] [Related]
16. Children and young adults with spinal muscular atrophy treated with nusinersen.
Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
[TBL] [Abstract][Full Text] [Related]
17. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.
Gavriilaki M; Moschou M; Papaliagkas V; Notas K; Chatzikyriakou E; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
Neurotherapeutics; 2022 Mar; 19(2):464-475. PubMed ID: 35178673
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures.
Kessler T; Sam G; Wick W; Weiler M
Eur J Neurol; 2024 Jan; 31(1):e16099. PubMed ID: 37823715
[TBL] [Abstract][Full Text] [Related]
20. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]